Related Experiment Videos
Acute myelofibrosis: response to recombinant human interferon alpha-2a
A F List1, T D Kummet, D M Kerr
1Department of Internal Medicine, Veterans Administration Medical Center, Phoenix, Arizona 85723.
Leukemia Research
|January 1, 1990
Summary
Recombinant human interferon alpha-2a shows promise for treating acute myelofibrosis, a rare bone marrow disorder. This therapy led to symptom improvement and hematologic recovery in two patients, suggesting significant potential for this condition.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Acute myelofibrosis is a rare myeloproliferative neoplasm.
- It is characterized by atypical megakaryocyte proliferation and a poor prognosis.
- Conventional therapies often yield limited efficacy.
Observation:
- Interferon alpha demonstrates antiproliferative effects on megakaryocyte progenitors.
- Two patients with acute myelofibrosis or acute myelodysplasia with myelofibrosis were treated with recombinant human interferon alpha-2a.
- Treatment followed failure of prior cytarabine-based chemotherapy regimens.
Findings:
- Interferon alpha therapy led to prompt symptom improvement and stabilized leukocyte counts.
- A reduction in circulating blast forms was observed in one patient.
- The second patient achieved complete hematologic recovery, including restored marrow cellularity and reduced fibrosis.
Implications:
- Recombinant human interferon alpha-2a may represent a viable therapeutic option for acute myelofibrosis.
- Further investigation into interferon alpha's efficacy in myeloproliferative neoplasms is warranted.
- This finding offers hope for patients with limited treatment alternatives.